ChartMill assigns a fundamental rating of 5 / 10 to AKCA.
ChartMill assigns a valuation rating of 1 / 10 to Akcea Therapeutics Inc (AKCA). This can be considered as Overvalued.
Akcea Therapeutics Inc (AKCA) has a profitability rating of 6 / 10.
The Earnings per Share (EPS) of Akcea Therapeutics Inc (AKCA) is expected to decline by -445.83% in the next year.
The dividend rating of Akcea Therapeutics Inc (AKCA) is 0 / 10 and the dividend payout ratio is 0%.